Therapeutic | Cemiplimab |
Target | PDCD1 |
Heavy Chain | EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Inovio Pharmaceuticals%3BISA Pharmaceuticals%3BRegeneron Pharmaceuticals%3BSanofi%3BSidney Kimmel Cancer Center%3BSillaJen Biotherapeutics%3BUniversity of Texas M. D. Anderson Cancer Center |
Conditions Approved | Squamous cell cancer |
Conditions Active | Cervical cancer%3BNon-small cell lung cancer%3BBasal cell cancer%3BOropharyngeal cancer%3BProstate cancer%3BFallopian tube cancer%3BGlioblastoma%3BMultiple myeloma%3BOvarian cancer%3BPeritoneal cancer%3BSolid tumours%3BB-cell lymphoma%3BCancer%3BHead and neck cancer%3BMalignant melanoma%3BRenal cell carcinoma |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]